Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|The Lancet Oncology|2017Cited by 378
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W. Roberts, John F. Seymour, Kathryn Humphrey et al.|Blood|2019Cited by 175
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, John F. Seymour, Michael Hallek et al.|Clinical Cancer Research|2018Cited by 161
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutré, Matthew S. Davids, Michael Y. Choi et al.|Blood|2018Cited by 132
Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or IdelalisibJeffrey A. Jones, Steven Coutré, Michael Y. Choi et al.|Blood|2016Cited by 58